Introduction
============

Infections caused by *Candida* species, extensively referred to as candidiasis, have been described as the most common fungal disease globally ([@B59]). Although *Candida albicans* is the species causing the highest number of infections in clinical settings, an increasing prevalence of other *Candida* species has been reported in the last years, being *Candida glabrata* the second most common species isolated from invasive candidiasis in North America and central and northern countries in Europe ([@B60]; [@B5]; [@B54]; [@B56]; [@B21]). In Spain, only *C. albicans* and *Candida parapsilosis* are more frequently isolated than *C. glabrata* from patients with fungemia ([@B37]).

Echinocandins are the first line antifungal therapy against *C. glabrata* infections, as this species generally presents low susceptibility to azole drugs. Echinocandins non-competitively inhibit the 1--3-β-[D]{.smallcaps}-glucan synthase, which is responsible for the synthesis of β-glucan polymers that confer integrity to the fungal cell wall. Nevertheless, an ever-growing number of echinocandin resistant clinical isolates have been reported worldwide in the last years and population studies in the United States and Denmark have shown an increase in echinocandin resistance rate ([@B2]; [@B33]; [@B73]; [@B6]), which is conferred by the presence of point mutations in specific regions (denominated as hot-spots) of *FKS* genes, which encode this enzyme's catalytic subunits ([@B47]).

*FKS* mutations have been reported to correlate with elevated *in vitro* minimal inhibitory concentrations (MICs) and clinical failure ([@B2]), yet an explanation for this increase in echinocandin resistant strains has not been proved. Several possibilities are being studied, such as strains proneness to acquire resistance as an answer to echinocandin exposure ([@B12], [@B13],[@B15]; [@B65]), the existence of hidden reservoirs in the human body of echinocandin resistant *C. glabrata* isolates ([@B66]; [@B36]; [@B45]; [@B40]) or molecular mechanisms like *MSH2* mutator phenotype ([@B28]; [@B39]; [@B19]; [@B42]; [@B70]; [@B11]).

Multilocus sequence typing (MLST) and microsatellite length polymorphism (MLP) have been described as typing methodologies with high discrimination power ([@B29]; [@B34]; [@B1]) for assesing *C. glabrata* strain relatedness.

The objective of the present study was to investigate the antifungal susceptibility, molecular mechanisms of echinocandin resistance and strain relatedness of a series of *C. glabrata* sequentially isolated from patients admitted in two hospitals in Madrid; and also the potential development of echinocandin resistance of susceptible *C. glabrata* isolates collected from 2013 to 2017 after *in vitro* exposure to a range of micafungin and anidulafungin concentrations.

Materials and Methods {#s1}
=====================

Yeast Isolates: Patients and Identification
-------------------------------------------

Eighteen *C. glabrata* strains sequentially isolated from five patients admitted in two centers (Hospital Universitario Puerta de Hierro and Hospital Universitario 12 de Octubre, both located in Madrid, Spain) were selected for showing a resistance profile against echinocandins. For two of these patients previous susceptible isolates were also available and analyzed. 89% (16/18) of them were obtained from blood cultures, while the two remaining were isolated from a catheter (one isolate from Patient 1) and from ascitic liquid (one isolate from Patient 2) ([Table 1](#T1){ref-type="table"}). For *in vitro* exposure to micafungin and anidulafungin assays, 14 *C. glabrata* strains collected from 2012 to 2017 from Hospital Universitario Puerta de Hierro, all isolated from blood cultures except one from ascitic liquid, were chosen for being susceptible to echinocandin drugs. All strains were isolated during routine diagnostic procedures at the hospitals and received at the Mycology Reference Laboratory of the Spanish National Centre for Microbiology. Isolates were characterized by morphological features and confirmed as *C. glabrata* by amplification and sequencing of their ITS1-5.8S-ITS2 regions ([@B74]). According to the Law 14/2007 of 3rd July on Biomedical Research and the Recommendation CM/Rec(2016)6 of the Committee of Ministers to member States on research on biological materials of human origin, no informed consent was required as no work was performed neither with samples of human origin nor with clinical data. The Mycology Reference Laboratory directly received fungal strains, isolated from the patients as routine diagnostic procedures in the hospital and referred to the National Centre for Microbiology according to routine procedures.

###### 

*Candida glabrata* sequential isolates from five patients admitted in two hospitals in Madrid: isolation dates, anatomic sources, *FKS2* alterations, *in vitro* susceptibility to echinocandins and fluconazole performed by EUCAST and genotyping results by MLST and MLP.

  Hospital               Patient   Strain        Isolation date   Anatomic source   *FKS 2* alteration   MIC EUCAST (mg/L)   Typing                                             
  ---------------------- --------- ------------- ---------------- ----------------- -------------------- ------------------- -------- ----------- ---------- ------------------ -------
  Hospital               1         CNM-CL9829    14/03/16         Blood culture     --                   0.007               0.25     0.007       4          205-243-134-267-   ST3
  Universitario Puerta             CNM-CL9835    17/03/16         Catheter          --                   0.015               0.25     0.007       4          262-325            
  de Hierro, Madrid,               CNM-CL9975    17/04/16         Blood culture     D666H                **0.125**           0.5      0.03        4                             
  Spain                            CNM-CL9877    17/06/16         Blood culture     L664R                **0.125**           1        **0.06**    2                             
                                   CNM-CL9889    07/07/16         Blood culture     L664R                **0.125**           1        **0.125**   2                             
                         2         CNM-CL9857    21/05/16         Blood culture     --                   0.03                0.25     0.007       2          205-243-134-267-   ST3
                                   CNM-CL9883    23/06/16         Ascitic fluid     D666E                **0.25**            1        **0.06**    4          262-325            
                                   CNM-CL9897    17/07/16         Blood culture     S663P                **2**               \>16     **\>2**     32                            
                         3         CNM-CL9931    21/10/16         Blood culture     ΔF659                **2**               \>16     **2**       2          187-251-122-270-   ST2
                                   CNM-CL9939    14/11/16         Blood culture     ΔF659                **2**               \>16     **2**       **64**     265-296            
                                   CNM-CL9991    23/11/16         Blood culture     ΔF659                **2**               \>16     **2**       **\>64**                      
                         4         CNM-CL9932    21/10/16         Blood culture     S663P                **2**               \>16     **2**       32         205-243-134-267-   ST3
                                   CNM-CL9981    12/11/16         Blood culture     S663P                **2**               \>16     **\>2**     32         262-325            
                                   CNM-CL9992    24/11/16         Blood culture     S663P                **2**               \>16     **\>2**     **64**                        
  Hospital               5         CNM-CL9646    25/02/15         Blood culture     D666N                **0.125**           0.5      **0.06**    **64**     237-236-128-270-   ST149
  Universitario 12 de              CNM-CL9775    11/11/15         Blood culture     D666N                **0.125**           0.5      **0.06**    2          262-290            
  Octubre, Madrid,                 CNM-CL9988    16/11/16         Blood culture     D666N                **0.25**            2        **0.06**    2                             
  Spain                            CNM-CL10047   16/01/17         Blood culture     ΔF659 + D666N        **\>4**             16       **2**       **64**                        

CNM-CL, Yeast Collection of the Spanish National Center for Microbiology; ANF, anidulafungin; CPF, caspofungin; MCF, micafungin; FLC, fluconazole; MLP, Microsatellite Length Polymorphism; bp, base pairs; MLST, Multilocus Sequence Typing; ST, sequence type. In bold letters, MIC values that are above the EUCAST clinical breakpoints stablished for those antifungals.

∗

MLP: ERG3-MTI-RPM2-GLM4-GLM5-GLM6

.

Antifungal Susceptibility Testing
---------------------------------

Minimal inhibitory concentrations were determined and confirmed following EUCAST 7.3.1 reference method for yeasts^[1](#fn01){ref-type="fn"}^. Antifungals tested were anidulafungin (range 0.007--4 mg/L; Pfizer, Madrid, Spain), micafungin (range 0.004--2 mg/L; Astellas Pharma Inc., Tokyo, Japan), caspofungin (range 0.032--16 mg/L; Merck Sharp & Dohme, United Kingdom) and fluconazole (range 0.125--64 mg/L; Pfizer, Madrid, Spain).

*Candida krusei* ATCC 6258 and *C. parapsilosis* ATCC 22019 were used as quality control strains in all test performed. The optical density of the inoculated plates was determined after 24 and 48 h of incubation at 35°C in a humid atmosphere, and strains were classified as susceptible or resistant according to clinical breakpoints established by EUCAST for *C. glabrata*: MIC \> 0.032 mg/L for micafungin, MIC \> 0.064 mg/L for anidulafungin and MIC \> 32 mg/L for fluconazole^[2](#fn02){ref-type="fn"}^.

DNA Extraction and *FKS* Sequencing
-----------------------------------

Genomic DNA of all isolates was extracted using the phenol-chloroform method ([@B71]). Molecular mechanisms of echinocandin resistance were studied by amplifying hot-spot regions 1 and 2 of *FKS1* and *FKS2* ([@B72]; [@B77]; [@B31]; [@B9]) as previously described with the following modifications: PCR reaction mixtures contained 25 ng of DNA, 0.2 μM of each primer, 0.2 μM of deoxynucleoside triphosphate (Roche, Spain), 5 μL of PCR 10× buffer (Applied Biosystems, Foster City, CA, United States), 2 mM of MgCl~2~ (Applied Biosystems, Foster City, CA, United States), 5.2% DMSO and 2.5 U of Taq DNA polymerase (Applied Biosystems, Foster City, CA, United States) in a final volume of 50 μL. PCRs conditions used were set as previously described ([@B31]), with an annealing temperature of 52°C for hot-spot regions 1 and 2 of *FKS1*, 53°C for hot-spot region 1 of *FKS2* and 58°C for hot-spot region 2 of *FKS2*. PCR amplicons were purified using Illustra ExoProStar 1-step (GE Healthcare Life Science, United Kingdom), and were sequenced after by Sanger method with an ABI3730XLsequencer (Applied Biosystems, Foster City, CA, United States). DNA sequences were analyzed with DNAStar Lasergene 12 software (DNAStar Inc., United States), and queried against *FKS1* (GenBank number CAGL0G01034g) and *FKS2* (GenBank number CAGL0K04037g) sequences of the type strain CBS 138^[3](#fn03){ref-type="fn"}^.

Assessment of Pooled Reservoir of Mixed Resistant Isolates
----------------------------------------------------------

For two patients with isolates harboring two different *FKS* mutations, the possible coexistence of diverse populations within the same sample was studied by randomly isolating ten colonies from the original samples sent from the hospital for DNA extraction and *FKS* amplification and sequencing.

Genotyping by MLST
------------------

Six housekeeping gene loci (*FKS, LEU2, NMT1, TRP1, UGP1*, and *URA3*) were studied for all isolates as previously described ([@B29]), with the following modifications: PCR reaction mixtures contained 25 ng of DNA, 1 μM of each primer, 0.05 μM of deoxynucleoside triphosphate, 5 μL of PCR 10× buffer, 2 mM of MgCl~2~, and 2.5 U of Taq DNA polymerase in a final volume of 50 μL. 5.2% of DMSO was added only to amplify *NMT1*. PCR conditions were set as described, but with an annealing temperature of 62°C for *FKS* and *URA3*. DNA sequences obtained were compared to *C. glabrata* MLST database^[4](#fn04){ref-type="fn"}^ to assign an allele number for each locus in order to define a sequence type (ST) or genotype according to the isolates' allelic profile.

Genotyping by MLP
-----------------

Six short tandem repeat markers described for *C. glabrata* (*ERG3, MTI, RPM2, GLM4, GLM5*, and *GLM6*) ([@B34]; [@B1]) were amplified by PCR for all isolates using forward labeled primers as previously described ([@B34]; [@B1]; [@B31]) with the following modifications: *GLM5* was labeled with HEX and *GLM6* with NED fluorochromes. PCR reaction mixtures contained 20 ng of DNA, 0.2 μM of deoxynucleoside triphosphate, 2 μL of PCR 10× buffer, 2.5 mM of MgCl~2~, 5 U of Taq DNA, 0.25 μM of *RPM2* and *ERG3* primers and 1 μM of *MTI, GLM4, GLM5*, and *GLM6* primers in a final volume of 20 μL. PCR program used from amplifying all markers consisted on an initial step of 5 min at 95°C, followed by 40 cycles of 95°C for 30 s, 57°C for 1 min and 72°C for 1 min, and an additional step of 7 min at 72°C. Amplicons were sized by capillary electrophoresis using Hi-Di formamide (Applied Biosystems, Foster City, CA, United States) and ROX 500 (Applied Biosystems, Foster City, CA, United States) as internal size standard, as described ([@B31]). Reactions were analyzed in duplicate, and fragment sizes were calculated using Peak Scanner software 1.0 (Applied Biosystems, Foster City, CA, United States).

*MSH2* Sequencing
-----------------

*MSH2* gene of sequentially isolated strains from patients was amplified and sequenced as previously described ([@B39]), and DNA sequences were queried against *MSH2* (Genbank number CAGL0I07733g) sequence of CBS 138 type strain.

*In vitro* Exposure to Growing Concentrations of Micafungin and Anidulafungin and Analysis of Generated Isolates
----------------------------------------------------------------------------------------------------------------

The potential development of micafungin and anidulafungin resistance of susceptible *C. glabrata* isolates was studied following a previously reported procedure ([@B12]) with some modifications.

Adjusted inocula (2 × 10^9^ to 4 × 10^9^ CFU/mL) from overnight cultures in 7 mL of yeast extract-peptone-dextrose broth of these isolates were cultured on Sabouraud plates containing eight different echinocandin concentrations (from 0.015 to 2 mg/L). Two different sets of experiments were tested at first. Plates at all concentrations were stroked at once with 100 μL of inocula and checked for growth daily for up to 5 days at 35°C. For progressive exposure, the lowest concentration plate was inoculated and checked for growth after 24 h at 35°C. If isolates were observed, they were cultured on a plate containing the next twofold concentration. The procedure was repeated up to highest concentration available.

After exposure, mutant prevention concentration (MPC) and mutant selection window (MSW) were calculated for each isolate as previously reported ([@B76]; [@B30]; [@B15]). Briefly, MPCs were defined as the lowest concentration that can totally inhibit fungal growth for each isolate after 5 days of incubation; for calculation purposes, MPC values that exceeded the highest concentration tested were transformed to the next dilution (i.e., if MPC \>2 mg/L, it was changed to MPC = 4 mg/L). MSWs were defined as the range of concentrations between the MIC, obtained by EUCAST method, and the MPC for each isolate.

Spontaneous growth frequency was also calculated as the ratio of viable colonies growing on 2 mg/L echinocandin-containing plates and the initial inoculum stroked in them, as some plates containing lower concentrations did not allow the counting of individual colonies.

Micafungin and anidulafungin susceptibility of up to four isolates selected from each growing concentration was performed, and the hot-spot regions 1 and 2 of *FKS1* and *FKS2* genes were sequenced.

Statistical Analysis
--------------------

All data obtained after *in vitro* exposure to echinocandins assays were compared using the Wilcoxon signed-rank test and the Fisher's exact test (IBM SPSS Statistics for Windows, version 22.0; United States), considering as statistically significant a *P-*value of \<0.05.

Results
=======

*In vitro* Susceptibility and Determination of *FKS* Mutations of Sequentially Isolated Strains
-----------------------------------------------------------------------------------------------

Control strains were within the accepted ranges according to EUCAST QC ranges for all antifungals tested.

As shown in [Table 1](#T1){ref-type="table"}, a wide range of fluconazole MIC values was found among isolates tested. All strains isolated from Patients 3, 4, and 5 were echinocandin resistant, according to EUCAST breakpoints established for anidulafungin and micafungin. For Patients 1 and 2, echinocandin susceptible isolates were also available and analyzed. The first resistant isolate from Patient 1 was only resistant to anidulafungin.

All resistant isolates harbored an echinocandin resistance related mutation at hot-spot region 1 of *FKS2* gene. Mutations found were S663P (*n* = 4), D666N (*n* = 4), ΔF659 (*n* = 4), L664R (*n* = 2), D666E (*n* = 1), and D666H (*n* = 1). No mutations were found at *FKS1* nor at hot-spot region 2 of *FKS2*. Each mutation was related to a different echinocandin resistant profile, as S663P and ΔF659 showed higher MIC values than the rest of the isolates that harbored other mutations.

Isolates With Different *FKS* Mutations Can Be Present in the Same Patient
--------------------------------------------------------------------------

Resistant isolates with different *FKS2* mutations were found in the same patient in two cases (Patient 1: D666H and L664R; and Patient 2: D666E and S663P). *FKS2* gene sequencing of 10 randomly selected colonies from the original samples of those isolates sent from the hospital led to the same *FKS* mutation in all of them, so the absence of a mixed culture of resistant isolates was confirmed.

MLST and MLP Analysis
---------------------

Three different STs were differentiated by MLST among the 18 isolates studied ([Table 1](#T1){ref-type="table"}). All isolates from the same patient had the same genotype. ST3 was found in three out of four patients of one hospital. The other two STs found were ST2 and a recently described ST149.

MLP methodology yield comparable results to those of MLST ([Table 1](#T1){ref-type="table"}).

*MSH2* Gene Sequencing
----------------------

All isolates from the same patient harbored the same SNPs in *MSH2* gene. Non-synonymous loss-of-function combined mutations V239L/A942T were found in all isolates coming from one patient, while the rest of isolates did not harbor any non-synonymous mutations in this gene.

Behavior of Echinocandin Susceptible *C. glabrata* Isolates From Patients 1 and 2 When *in vitro* Exposed to Growing Concentrations of Micafungin
-------------------------------------------------------------------------------------------------------------------------------------------------

*In vitro* exposure of echinocandin susceptible isolates CNM-CL9829, CNM-CL9835, and CNM-CL9857 from Patients 1 and 2 to micafungin generated *FKS* mutations that conferred echinocandin resistance after less than 48 h of incubation. Progressive exposure allowed the collection of isolates up to 2 mg/L, while colonies in direct exposure grew only up to 0.5 mg/L. All colonies obtained in plates containing 0.015 and 0.03 μg/mL were susceptible to micafungin and anidulafungin and had no mutations in hot-spot regions of *FKS* genes. All isolates growing from 0.06 μg/mL were resistant to both echinocandins and harbored the resistant related mutation S663P in *FKS2* gene ([Figure 1](#F1){ref-type="fig"}).

![Results from *in vitro* direct and progressive exposure to micafungin of susceptible *C. glabrata* isolates from Patients 1 and 2.](fmicb-10-01585-g001){#F1}

Correlation Between Potential Development of Echinocandin Resistance After *in vitro* Exposure to Micafungin and Anidulafungin of Echinocandin Susceptible Isolates of *C. glabrata* and Their Genotype
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[Table 2](#T2){ref-type="table"} shows genotyping results by MLST and MLP, echinocandin susceptibility by EUCAST, MPC and MSW after *in vitro* direct exposure to micafungin and anidulafungin of fourteen echinocandin susceptible *C. glabrata* strains collected from 2012 to 2017 from Hospital Universitario Puerta de Hierro, total number of colonies analyzed per isolate (up to 4 colonies per concentration) after 5 days of incubation and *FKS* mutations found.

###### 

Isolation year, micafungin and anidulafungin MIC values, mutant prevention concentration (MPC), mutant selection window (MSW), total number of colonies analyzed and *FKS* alterations found in them after 5 days of incubation for each isolate, and their genotype by MLP and MLST.

  Strain            Isolation year   Anidulafungin exposure   Micafungin exposure   MLP^∗^ (bp)   MLST (ST)                                                                                                                              
  ----------------- ---------------- ------------------------ --------------------- ------------- ----------- ------------------ ------- -------------- ------------- ------------ --------------------------- ------------------------- -----
  **CNM-CL9210**    2012             0.03                     2                     0.03--2       14          --                 0.007   4              0.007--4      27           2-S663P                     237-236-128-270-262-290   149
  **CNM-CL9215**    2012             0.03                     2                     0.03--2       13          --                 0.007   4              0.007--4      26           2-S663P                     237-236-128-270-262-290   149
  **CNM-CL9269**    2012             0.03                     4                     0.03--4       26          2-S663P            0.007   4              0.007--4      27           2-S663P                     205-243-134-267-262-325   3
  **CNM-CL9332**    2013             0.03                     4                     0.03--4       19          1-S629P; 2-F659Y   0.015   4              0.015--4      27           2-S663P                     215-242-134-282-265-298   19
  **CNM-CL9342**    2013             0.06                     2                     0.06--2       11          --                 0.015   0.25           0.015--0.25   13           2-ΔF659                     215-242-134-282-265-298   19
  **CNM-CL9392**    2013             0.06                     4                     0.06--4       26          2-S663P            0.015   4              0.015--4      27           2-S663P                     215-242-134-282-265-298   19
  **CNM-CL9555**    2014             0.03                     4                     0.03--4       26          2-S663P            0.015   4              0.015--4      20           2-ΔF659                     205-243-134-267-262-325   3
  **CNM-CL9571**    2014             0.03                     2                     0.03--2       12          --                 0.015   0.5            0.015--0.5    13           --                          205-243-134-267-262-325   3
  **CNM-CL9780**    2015             0.03                     4                     0.03--4       25          2-S663P            0.007   4              0.007--4      20           1-S629P; 2-ΔF659; 2-L662W   215-242-134-282-265-298   19
  **CNM-CL9785**    2015             0.03                     0.5                   0.03--0.5     13          --                 0.007   4              0.007--4      26           2-S663P                     205-243-134-267-262-325   3
  **CNM-CL9862**    2016             0.03                     0.5                   0.03--0.5     10          --                 0.007   0.5            0.007--0.5    11           --                          230-243-128-270-262-325   6
  **CNM-CL9906**    2016             0.03                     4                     0.03--4       18          2-S663P            0.007   0.5            0.007--0.5    14           2-ΔF659                     205-243-134-267-262-325   3
  **CNM-CL10190**   2017             0.03                     4                     0.03--4       16          2-ΔF659            0.007   0.5            0.007--0.5    19           --                          205-243-134-267-262-325   3
  **CNM-CL10194**   2017             0.03                     4                     0.03--4       29          2-S663P            0.007   2              0.007--2      26           2-ΔF659; 2-S663P            205-243-134-267-262-325   3
  **Global**        **GM**                                    0.03                  2.44                      Total = 258                0.01           1.72                       Total = 296                                           
                    **Range**                                 0.03--0.06            0.5--\>2      0.03--\>2                              0.007--0.015   0.25--\>2     0.007--\>2                                                         

GM, geometric mean. FKS alteration: (1) mutation in FKS1 gene; (2) mutation in FKS2 gene.

∗

MLP: ERG3-MTI-RPM2-GLM4-GLM5-GLM6

.

Four different STs were found among these strains. The most common one was ST3, found in half of the isolates (*n* = 7), followed by ST19 (29%, *n* = 4), ST149 (14%, *n* = 2), and ST6 (7%, *n* = 1).

Mutant prevention concentration values after anidulafungin and micafungin exposure differ widely between strains ([Table 2](#T2){ref-type="table"}), although no significant differences were found between the geometric mean of MPCs after anidulafungin exposure and after micafungin exposure after 5 days of incubation (2.44 mg/L versus 1.72 mg/L).

Geometric mean of spontaneous growth frequency for micafungin-containing plates had no significant difference with that for anidulafungin-containing plates (8 × 10^-8^ versus 4.1 × 10^-8^; *p* = 0.78), and ranges were very similar for both of them (4.1 × 10^-7^ to 3.2 × 10^-9^ in the presence of micafungin and 3.7 × 10^-7^ to 5.3 × 10^-9^ in the presence of anidulafungin).

A total number of 296 and 258 isolates were analyzed after micafungin and anidulafungin exposure, respectively ([Figure 2](#F2){ref-type="fig"}). The lowest concentrations of these antifungals in which resistant colonies harboring *FKS* mutations were found were 0.06 mg/L and 0.12 mg/L, respectively, while they appeared up to the highest concentration tested in both cases, 2 mg/L. 58% of the isolates yielded in micafungin plates harbored *FKS* mutations related to echinocandin resistance, which was a significantly higher number than the 42% of the isolates that did so after anidulafungin exposure (*p* \< 0.0001). The most prevalent mutation found was S663P (no significant differences were found among the frequency of occurrence of this substitution after exposure to both echinocandins: *n* = 159 from MCF plates and *n* = 102 from AND plates; 92.4 and 93.5% of *FKS* mutant isolates generated, *p* = 0.8147), followed by ΔF659 (its appearance rate was close to be significantly different after exposure to both antifungals: *n* = 10 from MCF plates and *n* = 1 from AND plates, *p* = 0.0552), F659Y (*n* = 1 from AND plates) and L662W (*n* = 1 from MCF plates) in hot-spot 1 from *FKS2* gene and S629P (*n* = 5 from AND plates and *n* = 2 from MCF plates) in hot-spot 1 from *FKS1* gene. All of these isolates were echinocandin resistant by EUCAST, and their *FKS* mutations and resistance were stable and reproducible after subculturing on antifungal-free plates. The same isolate could develop different *FKS* mutations after exposure. Out of the total number of isolates analyzed after micafungin and anidulafungin exposure, 1 and 19%, respectively, were resistant to micafungin and/or anidulafungin but did not carry any *FKS* mutation.

![*FKS* mutant and wild-type colony rates with their MIC ranges **(Top)**, and *FKS* mutations found with range of MIC values per mutation **(Bottom)** after *in vitro* exposure to micafungin and anidulafungin.](fmicb-10-01585-g002){#F2}

Discussion
==========

The increasing number of *C. glabrata* clinical isolates reported showing decreased susceptibility for echinocandins is a growing concern. Recent studies indicate that echinocandin resistance rates among *C. glabrata* clinical isolates have risen worldwide ([@B48]; [@B16]; [@B37]; [@B58]; [@B49]; [@B23]; [@B41]). Resistance has been reported to easily develop *in vitro* ([@B12], [@B13],[@B15]; [@B65]) and in patients after echinocandin exposure ([@B27]; [@B68]; [@B2]; [@B10]; [@B64]), being conferred by the presence of point mutations in hot-spot regions of *FKS1* and *FKS2* genes ([@B22]; [@B61]) that have been associated with higher MICs and therapeutic failure ([@B68]). Our study provides a new insight into the development of echinocandin resistance of *C. glabrata* strains both sequentially isolated from several patients and after *in vitro* exposure to growing concentrations of micafungin and anidulafungin.

*FKS* Mutations
---------------

All isolates from five patients admitted in two Spanish hospitals that were resistant to at least one echinocandin carried mutations in *FKS2* gene ([@B77]; [@B22]; [@B53]). The most common ones found were S663P and ΔF659, as in previous studies ([@B77]; [@B7]; [@B22]). Some isolates carried less frequently found substitutions L664R, D666E, and D666N ([@B22]; [@B62]; [@B14]) and, although it has been found after *in vitro* exposure to the novel antifungal rezafungin ([@B53]), we believe that this is the first time that D666H mutation is reported in a clinical isolate.

From two of the studied patients, echinocandin susceptible isolates without mutations in *FKS* genes were detected before the isolation of the resistant ones, indicating that echinocandin resistance could had been acquired due to therapy, as previously reported in other studies ([@B25]; [@B72]; [@B44]; [@B26]; [@B27]; [@B68]; [@B2]; [@B51]; [@B7]). All isolates with *FKS* mutations had MIC values above the clinical breakpoints established by EUCAST both for anidulafungin and for micafungin, except one isolate that was resistant to anidulafungin but not to micafungin despite harboring an *FKS* mutation (D666H). This case has been described before ([@B4]; [@B68]; [@B45]; [@B12]) but should be taken into account when testing only one echinocandin to detect resistance.

Glucan synthase enzyme sensitivity has been described to be affected by *FKS* mutations on different degrees ([@B35]). In this study, S663P and ΔF659 were associated with higher echinocandin MIC values, as previously reported ([@B3]). Isolates harboring D666H, D666N, D666E, and L664R substitutions showed lower MIC values and conferred weaker echinocandin resistance. Patient 5 simultaneously carried ΔF659 and D666N substitutions in CNM-CL10047 isolate, which had high echinocandin MIC values. A double mutation in these two amino acid positions has been previously found (F659S and D666E) ([@B62]), but we are reporting the association of ΔF659 and D666N for the first time.

As we found sequential isolates from the same patient carrying different *FKS* mutations, we studied the possible coexistence of a mixed population of resistant isolates within the same sample, confirming its absence. Nevertheless, this experiment had some limitations, as the original samples sent from the hospital could be an already isolated colony. Serial *C. glabrata* isolates from the same patient showing different antifungal resistance profiles due to the selective pressure induced by changes in antifungal treatment have been previously reported ([@B24]; [@B43]).

Genotyping
----------

Strain relatedness was determined by MLST and MLP, which led to similar results evidencing that both methodologies are equally useful for genotyping purposes, as previously reported ([@B18]). Nevertheless, in other investigations a higher number of genotypes were obtained by MLP than by MLST ([@B42]; [@B11]). Isolates from the same patient seemed to have a clonal origin by using these two typing techniques, although the use of next generation sequencing in order to compare their genomes would be necessary to prove if they are isogenic. The most frequent genotype among these patients was ST3, which has been reported as one of the most prevalent STs worldwide ([@B29]; [@B55]; [@B41]; [@B8]; [@B19]; [@B57]). No association between echinocandin resistance development and genetic type was found, which was in agreement with other reports ([@B29]; [@B1]). A recent study has found a link between certain STs and reduced susceptibility to fluconazole ([@B57]), something that we did not see when performing fluconazole susceptibility to all the isolates. Genotypes were also independent of the anatomic source of the isolates ([@B52]).

MSH2
----

*MSH2* mismatch repair gene involved in DNA repair has been described as a promoter of the acquisition of resistance to antifungals of *C. glabrata* ([@B39]), but in this study all isolates belonging to the same patient had the same *MSH2* gene sequence, regardless their susceptibility pattern to echinocandins. Echinocandin susceptible isolates with and without *MSH*2 mutations yielded echinocandin resistant isolates with *FKS* mutations. Also, *FKS* mutant isolates for three patients had a wild-type *MSH2* gene. Altogether, this supports that echinocandin resistance cannot be explained by *MSH2* mutator phenotype, as previously reported ([@B28]; [@B38]; [@B8]; [@B19]; [@B42]; [@B70]; [@B11]). Likewise, no clear association between *MSH2* sequence and increased fluconazole resistance or genotypes was detected on these isolates either ([@B8]; [@B11]), although a correlation with specific genetic types was previously described ([@B28]; [@B19]; [@B42]). These results confirm that *MSH2* substitutions may be constitutive variations from the gene rather than resistance-related or genotype-related mutations ([@B20]). Still, it cannot be dismissed that *MSH2* may just be one of a higher number of *C. glabrata* genes involved in mismatch repair mechanisms influencing on the development of antifungal resistance, as it happens for other yeasts ([@B50]; [@B17]).

*In vitro* Resistance Development
---------------------------------

It is of interest to gain a deeper understanding of how *C. glabrata* isolates behave when *in vitro* exposed to echinocandins, and correlate these results with clinical findings or to anticipate to possible clinical cases. Susceptible isolates from Patients 1 and 2 were *in vitro* exposed to a range of growing concentrations of micafungin, obtaining echinocandin resistant and *FKS* mutant colonies after exposure to the lowest micafungin concentration considered resistant by EUCAST (0.06 mg/L) in less than 48 h of incubation. These results are in agreement with those previously reported ([@B12], [@B13]). In our study, *FKS* mutations found after *in vitro* micafungin exposure were different from those isolated from the patients, something that evinces *C. glabrata*'s facility to develop resistance and to acquire different mutations under drug pressure.

It has been hypothesized that certain STs may have a better competence than others to acquire resistance through antifungal exposure at different frequencies ([@B55]; [@B41]). Therefore, we aimed to compare the potential development of *in vitro* echinocandin resistance of a set of susceptible *C. glabrata* isolates collected in 6 years from one hospital after exposure to a range of micafungin and anidulafungin concentrations, and to correlate this with their genotype. MLST and MLP revealed four different STs among these fourteen isolates. Not all strains isolated on the same year showed the same ST in all cases and no clear trend on the evolution of *C. glabrata* population in this center was found. No statistical differences were found among MPC values and spontaneous growth frequencies for both agents, something in concordance with previous results published ([@B15]). Results in our study varied between strains, being echinocandin resistant colonies harboring *FKS* mutations isolated from plates containing the first micafungin and anidulafungin concentrations considered as resistant by EUCAST. Nevertheless, a significantly higher *FKS* mutant rate was found after micafungin exposure than after anidulafungin selection.

*In vitro* micafungin and anidulafungin exposure allowed the selection of different *FKS* mutations grown at different concentrations and even at the same one for some strains. S663P was the most frequently found mutation following exposure to both echinocandins, although in previous *in vitro* selection studies ΔF659 was the most prevalent one ([@B15]; [@B65]), which was the second most common one in our study.

We found 53 colonies with MICs onefold or twofold above the established breakpoint for anidulafungin that did not carry any *FKS* mutations. This finding was especially detected after exposure to anidulafungin, as 50 colonies out of 258 isolated were anidulafungin resistant but *FKS* wild-type, while only three out of 296 colonies analyzed after micafungin exposure had this categorization. This similar case and also echinocandin susceptible isolates harboring *FKS* substitutions have been previously found, both in clinical isolates and after *in vitro* exposure ([@B22]; [@B61]; [@B67], [@B65]; [@B53]). Precisely, anidulafungin resistance, according to EUCAST breakpoints, was vastly sensitive (100%; all colonies that were *FKS* mutant showed a MIC value above its clinical breakpoint for EUCAST) but showed lower specificity (80.6%; as 53 colonies out of a total of 273 that were *FKS* wild-type showed MICs above the EUCAST breakpoint) than in another study ([@B65]) for the identification of *in vitro* selected *FKS* mutant colonies. Micafungin showed higher sensitivity (99.3%; 279 out of 281 isolates that harbored *FKS* mutations were micafungin resistant according to EUCAST breakpoint) and similar specificity (99.8%; only one *FKS* wild-type colony was micafungin resistant) to those reported in that study. Taken together, this confirmed that both antifungals are suitable echinocandin resistance markers for *C. glabrata*, unlike caspofungin ([@B69]; [@B32]).

We concluded that the development of echinocandin resistance in *C. glabrata* after *in vitro* exposure to micafungin and anidulafungin has no association with specific genotypes. Results obtained in all these *in vitro* studies on how echinocandin susceptible *C. glabrata* strains are able to develop resistance after exposure to low echinocandin concentrations supports the fact that *C. glabrata* is able to colonize and survive in certain reservoirs of the human body, such as the abdomen ([@B66]), the peritoneum ([@B36]), the gastrointestinal tract ([@B40]) or the mucosal surfaces ([@B45]), due to long-term penetration of echinocandins in lower concentrations than those that prevent resistance acquisition. Since sometimes this required dose could lead to toxicity, the use of newly developed drugs that target the 1--3-β-[D]{.smallcaps}-glucan synthase, such as ibrexafungerp (Scynexis, Jersey City, NJ, United States), which has shown potential effectiveness against echinocandin resistant *C. glabrata* isolates ([@B75]), or rezafungin (Cidara, San Diego, CA, United States), which has an extended-interval administration due to its improved pharmacodynamics ([@B63]) could help to overcome echinocandin resistance. Nevertheless, *C. glabrata* strains have been *in vitro* exposed to both drugs, leading to similar results than those against other echinocandins ([@B53]; [@B46]), so further research for new compounds that have a role on novel mechanisms of action is assured.

In summary, the present study analyzes the relevance of certain hypothesis raised on the increase of echinocandin resistance in *C. glabrata*, and sheds light on several important aspects related to its acquisition and development, both in genetically related serial isolates from the same patient and after *in vitro* exposure to micafungin and anidulafungin.
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